Bayer HealthCare

Bayer to acquire Steigerwald Arzneimittelwerk

Friday, May 17, 2013 11:56 AM

Bayer has signed an agreement to acquire 100% of the shares of Steigerwald Arzneimittelwerk, a Darmstadt, Germany-based privately held pharmaceutical company specializing in pharmacy-only herbal medicines.

More... »

Bayer to acquire Conceptus

Monday, April 29, 2013 10:50 AM

Bayer HealthCare has signed a merger agreement with Conceptus, a Mountain View, Calif.-based developer of the Essure procedure, a non-surgical permanent birth control method.

More... »

Janssen launches global cardiovascular research program, five new studies

Friday, March 8, 2013 10:47 AM

Janssen Research & Development has launched EXPLORER, a comprehensive, global research program for XARELTO (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.

More... »

Bayer's Stivarga receives FDA approval for GIST

Tuesday, February 26, 2013 12:27 PM

The FDA has approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

More... »

Janssen, Bayer, Portola form clinical collaboration

Friday, February 8, 2013 11:17 AM

Janssen Pharmaceuticals has signed a clinical collaboration agreement with Portola Pharmaceuticals and Bayer HealthCare to evaluate the safety of PRT4445—an investigational-stage antidote for Factor Xa inhibitors—in healthy volunteers who have been administered the oral anticoagulant Xarelto (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of Xarelto in emergency situations.

More... »

Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

Friday, December 14, 2012 12:07 PM

Bayer HealthCare has submitted a New Drug Application (NDA) to the FDA seeking approval for radium Ra 223 dichloride (radium-223), a fast tracked investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

More... »

Bayer HealthCare strengthens position in Russia

Friday, November 2, 2012 02:21 PM

Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders.

More... »

FDA grants Bayer’s Stivarga NDA priority review

Thursday, November 1, 2012 11:49 AM

Bayer HealthCare and Onyx Pharmaceuticals, a biopharmaceutical company based in South San Francisco, announced today that the FDA has granted priority review to the New Drug Application (NDA) for Stivarga (regorafenib) tablets.

More... »

Bayer to acquire Schiff Nutrition International for $ 1.2B

Wednesday, October 31, 2012 09:15 AM

Bayer HealthCare has signed a merger agreement to acquire Schiff Nutrition International, a company offering vitamins and nutritional supplements in the U.S. and other countries, for $1.2 billion, representing a value of $34 per share in cash.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »